top of page
< Back

Rotigotine


Mechanism of action:

Rotigotine is a dopamine receptor agonist. Rotigotine acts on D1, D2, and D3 receptors, with the highest affinity for D3 receptors and the lowest affinity for D1 receptors. After these receptors are activated by rotigotine, adenylyl cyclase is inhibited through Gi/o protein coupling, cAMP levels fall, and the motor circuits of the basal ganglia are regulated.

Reference(s):

1. Giladi N et al. (2007). Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 


2. Chen JJ et al. (2009). Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Pharmacotherapy. 


3. Perez-Lloret S et al. (2013). Rotigotine transdermal patch for the treatment of Parkinson's Disease. Fundam Clin Pharmacol.

bottom of page